Alzheimer's drug market to more than triple to $13.3 billion in 2019 in top seven markets, fuelled by new biologic agents

The emergence of new agents that have the potential to affect disease progression, the Alzheimer's disease drug market will more than triple, from $4.3 billion in 2009 to $13.3 billion in 2019 in the USA, France, Germany, Italy, Spain, the UK and Japan, forecasts advisory firm Decision Resources.

DR’s Pharmacor 2010 findings from the topic titled Alzheimer's Disease reveal that growth will be driven primarily by the first biologic agents to enter the market - Eli Lilly's solanezumab and Johnson & Johnson/Pfizer's bapineuzumab. These anti-beta-amyloid monoclonal antibodies (MAbs), which have the potential to slow the rate of neurodegeneration and cognitive decline, together will earn more than $6.9 billion in the world's major pharmaceutical markets in 2019.

Donepezil will maintain AChEIs drug class over next decade